Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review
A St Clair-Jones, F Prignano, J Goncalves… - Rheumatology and …, 2020 - Springer
Injection-site pain (ISP) is a subjective side effect that is commonly reported with the
subcutaneous administration of biological agents, yet it may only be a concern to some …
subcutaneous administration of biological agents, yet it may only be a concern to some …
Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design
J Stevenson, R Poker, J Schoss, M Campbell… - Advanced Drug Delivery …, 2024 - Elsevier
Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional
intravenous route of administration, potentially offering notable advantages for both patients …
intravenous route of administration, potentially offering notable advantages for both patients …
Flavonoids as antidiabetic agents
Y Cahyana, T Adiyanti - Indonesian Journal of Chemistry, 2021 - journal.ugm.ac.id
Flavonoids are polyphenol compounds that exert many potential health benefits, including
diabetes type-II, which is the third most common disease that causes death, right after …
diabetes type-II, which is the third most common disease that causes death, right after …
Patient-centred care in type 2 diabetes mellitus–Key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report
K Fritzen, C Stautner, O Schnell - Diabetes research and clinical practice, 2019 - Elsevier
Abstract In 2018, the American Diabetes Association (ADA) and the European Association
for the Study of Diabetes (EASD) published a consensus report on the management of …
for the Study of Diabetes (EASD) published a consensus report on the management of …
'Is Insulin Right for Me?'Development of a theory-informed, web-based resource for reducing psychological barriers to insulin therapy in type 2 diabetes
Objective To develop a theory and evidence-based web intervention to reduce
psychological barriers towards insulin therapy among adults with non-insulin-treated type 2 …
psychological barriers towards insulin therapy among adults with non-insulin-treated type 2 …
Key strategies for overcoming psychological insulin resistance in adults with type 2 diabetes: The UK subgroup in the EMOTION study
EG Balogh, M Perez-Nieves, D Cao, II Hadjiyianni… - Diabetes Therapy, 2020 - Springer
Introduction Many patients with type 2 diabetes mellitus (T2DM) delay initiation of insulin
therapy despite healthcare professional (HCP) advice. This phenomenon has been referred …
therapy despite healthcare professional (HCP) advice. This phenomenon has been referred …
Predictors of glycemic control after decline of insulin therapy by patients with type 2 diabetes
Aim Decline of insulin therapy by patients is common but poorly investigated. We conducted
this study to determine patient and treatment characteristics predictive of glycemic control …
this study to determine patient and treatment characteristics predictive of glycemic control …
Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia
M He, M Deng, J Wang, P Fan… - Experimental and …, 2021 - spandidos-publications.com
The safety and efficacy of dipeptidyl peptidase‑4 inhibitors in patients newly diagnosed type
2 diabetes mellitus (T2DM) with severe hyperglycaemia have remained to be sufficiently …
2 diabetes mellitus (T2DM) with severe hyperglycaemia have remained to be sufficiently …
[HTML][HTML] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal …
AA Jammah - Primary Care Diabetes, 2021 - Elsevier
Background Fixed-dose combinations of insulin glargine/lixisenatide (IGlarLixi) or insulin
degludec/insulin aspart (IDegAsp) constitute treatment intensification in type 2 diabetes …
degludec/insulin aspart (IDegAsp) constitute treatment intensification in type 2 diabetes …
Percepción de la aceptación a la terapia con insulina en pacientes con diabetes mellitus tipo 2 en el Centro de Salud de Ricaurte. Cuenca, 2023
KI Pintado Illescas, JM Quezada Morocho - 2023 - dspace.ucuenca.edu.ec
Background: Type 2 diabetes mellitus (DM2) is a chronic disease in constantly increasing
worldwide, insulin is a fundamental pillar of treatment, however, on many occasions, its …
worldwide, insulin is a fundamental pillar of treatment, however, on many occasions, its …